High school student gets an early start in stem cell research at USC – USC News
USC News |
High school student gets an early start in stem cell research at USC
USC News More impressively, he was familiar with these terms before starting his summer internship in the lab of Andy McMahon, kidney researcher and director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. “I knew I … |
FierceBiotech |
News of Note—New CRISPR R&D head; Homology $83.5M raise; Cellectar collab
FierceBiotech After jumping ship from a troubled AstraZeneca, its former head of oncology, Tony Ho, M.D., has climbed aboard preclinical gene editing biotech CRISPR Therapeutics. He becomes EVP and head of R&D at the company and will oversee its global research … |
|
Chiesi Ends Collaboration with uniQure on Hemophilia B Gene Therapy Candidate
Genetic Engineering & Biotechnology News Chiesi Group has ended its four-year-old collaboration with uniQure to co-develop and license a gene therapy for hemophilia B and has returned its development and commercialization rights to the gene therapy candidate in Europe and other areas, uniQure … |
|
Increased α5β1 integrin could improve tumor cell-killing performance in geriatric patients
EurekAlert (press release) This report showed that CAR–T cells from geriatric donors have specific defects that lead to decreased tumor cell-killing performance, when compared to younger donors. The study also uncovered the Geri-T method, which increases α5β1 integrin expression … |
|
Berkeley Files Opening Brief in CRISPR Appeal
JD Supra (press release) In considering the evidence before it, the PTAB gave great weight to contemporaneous, cautious statements in the art in view of Professor Doudna’s disclosure of in vitro CRISPR activity regarding whether the system would work in eukaryotic cells … |
HealthNewsReview.org |
PODCAST #33: The Wild West of stem cells
HealthNewsReview.org In this podcast you’ll hear from George Gibson (a patient left blind after a dubious stem cell intervention), Leigh Turner PhD (a bioethicist who’s been following the stem cell marketplace closely), and Drs. Jeanne Loring and Paul Knoepfler – two PhD … |